Integrative single-cell and spatial transcriptomics with explainable AI reveal lethal prognostic axis in prostate cancer

Read full text
Authors: Qintao Ge, Zhenda Wang, Yangyun Wang, Yangyun Wang, Tonghui Chu, Zhongyuan Wang, Zhongyuan Wang, Wenkai Zhu, Youzhao Zhang, Yonghao Chen, Dingwei Ye, Wenhao Xu
+3 more Zhong Wang, Zhong Wang, Mierxiati Abudurexiti
Cited by: 7
References: 37

Abstract

Prostate cancer (PCa) remains clinically heterogeneous. We integrated single-cell and spatial transcriptomics with explainable machine learning to define a lethal tumor axis and establish an interpretable prognostic model. From 141,986 high-quality single cells spanning localized, hormone-sensitive, and castration-resistant PCa, we identified a malignant C4 epithelial subpopulation characterized by high chromosomal instability, androgen receptor and cell-cycle activation, and stemness potential. Spatial mapping further revealed immune-enriched yet suppressive niches, where fibroblasts and myeloid cells coexisted with exhausted lymphocytes, reflecting functional immune imbalance. We benchmarked 101 machine learning pipelines, selecting a Lasso plus PLS-Cox model that achieved strong concordance across independent cohorts. The C4-based risk score independently predicted recurrence-free survival after adjustment for age, Gleason score and T stage, and a nomogram combining this score with clinical variables showed good discrimination. SHAP interpretation highlighted MT1M, PCSK1N, and ACSL3 as major risk-driving features. PCSK1N was progressively upregulated from normal prostate to castration-resistant disease and promoted proliferation, clonogenicity, migration and enzalutamide resistance, while its inhibition sensitized organoids and xenografts to AR-targeted therapy. These findings define a C4-centered lethal tumor axis and provide an explainable, experimentally supported framework for prognostic stratification in PCa.

Fields of Study & Subjects

Single-cell and spatial transcriptomics Prostate Cancer Treatment and Research Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
npj Digital Medicine
Publisher
Springer Science and Business Media LLC
Volume
9
Issue
1
Pages
119–119
Publication date
6 January 2026
Language
EN